Michael Landine - Alkermes Plc Senior Vice President - Corporate Development
| ALKS Stock | USD 28.78 1.08 3.90% |
President
Mr. Michael J. Landine is Senior Vice President Corporationrationrate Development, Chief Risk Officer of the Company. Prior to assuming his current positions, from September 2011 to March 2018, Mr. Landine served as Senior Vice President, Corporationrationrate Development of Alkermes, Inc. From May 2007 to September 16, 2011, Mr. Landine served as Senior Vice President, Corporationrationrate Development of Alkermes, Inc. From March 1999 until May 2007, Mr. Landine served as Vice President, Corporationrationrate Development of Alkermes, Inc. From March 1988 until June 1998, he was Chief Financial Officer and Treasurer of Alkermes, Inc. Mr. Landine is a member of the board of directors of Kopin Corporationrationration, a publicly traded manufacturer of components for electronic products, and was a member of the board of directors of ECI Biotech, a privately held protein sensor company and GTC Biotherapeutics, Inc., a publicly traded biotechnology company. Mr. Landine was previously a Certified Public Accountant. since 2018.
| Age | 70 |
| Tenure | 6 years |
| Address | Connaught House, Dublin, Ireland, D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Web | https://www.alkermes.com |
Michael Landine Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Landine against Alkermes Plc stock is an integral part of due diligence when investing in Alkermes Plc. Michael Landine insider activity provides valuable insight into whether Alkermes Plc is net buyers or sellers over its current business cycle. Note, Alkermes Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alkermes Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Landine over six months ago Disposition of 1308 shares by Michael Landine of Alkermes Plc at 32.18 subject to Rule 16b-3 |
Alkermes Plc Management Efficiency
The company has return on total asset (ROA) of 0.0898 % which means that it generated a profit of $0.0898 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2923 %, meaning that it created $0.2923 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.27 in 2024. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 12.1 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Juan Sanchez | Intracellular Th | 53 | |
| Robert Davis | Intracellular Th | 73 | |
| Crystal Muilenburg | Evolus Inc | 44 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| John Bardi | Intracellular Th | N/A | |
| Lisa Escudero | Phibro Animal Health | 62 | |
| Ryan Spencer | Dynavax Technologies | 46 | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Riccardo Manetti | Dynavax Technologies | N/A | |
| Michael Ostrach | Dynavax Technologies | 72 | |
| Scott Dreyer | Collegium Pharmaceutical | 52 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Jonathan Bendheim | Phibro Animal Health | 48 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| Samson Li | Phibro Animal Health | 52 | |
| Saumen Chakraborty | Dr Reddys Laboratories | 58 | |
| Stephen Carey | ANI Pharmaceuticals | 53 | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Mark Neumann | Intracellular Th | 61 | |
Management Performance
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.0898 |
Alkermes Plc Leadership Team
Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Norman, Senior Relations | ||
| David Gaffin, Senior Vice President Chief Legal Officer | ||
| Richard Pops, Chairman and CEO | ||
| Iain Brown, Chief Accounting Officer | ||
| Blair Jackson, Executive Officer | ||
| Declan OConnor, Health Environment | ||
| Samuel Parisi, Interim Finance | ||
| Stephen Schiavo, Senior Resources | ||
| Michael Landine, Senior Vice President - Corporate Development | ||
| Thomas Harvey, Chief IT | ||
| Craig MD, Executive Officer | ||
| Floyd MD, Founder | ||
| David JD, Chief VP | ||
| Sandra Coombs, Senior Relations |
Alkermes Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | ||||
| Return On Asset | 0.0898 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 4.11 B | ||||
| Shares Outstanding | 161.8 M | ||||
| Shares Owned By Insiders | 1.31 % | ||||
| Shares Owned By Institutions | 98.69 % | ||||
| Number Of Shares Shorted | 16.12 M | ||||
| Price To Earning | (38.45) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.